PRAGUE, Aug. 27,
2024 /PRNewswire/ -- Continuous research by
Dr. Yael Halaas (USA) and Dr.
Woraphong Manuskiatti (Thailand)
has unveiled the first evidence on the longer-term effectiveness of
EMFACE, the innovative facial treatment developed by BTL.
Launched in 2022, EMFACE is the first non-invasive procedure
that treats multiple facial tissues, from muscle to skin.
"EMFACE is the only procedure capable of lifting the framework
of one's face completely non-invasively. Patients can anticipate a
natural volumizing and lifting effect", says Dr Halaas, one of
the original investigators of EMFACE technology.
EMFACE combines Synchronized RF and
HIFES™ technologies, patented by BTL. It has become
a foundational treatment for many patients seeking aesthetic
improvements to their faces and is increasingly popular when used
alongside injectable treatments.
Dr. Halaas recently introduced a case series evaluating
patients one year after their EMFACE treatments. Her findings
revealed that, on average, 68% of the original volumetric changes
are sustained. This includes a 2.6-ml increase in upper cheek
volume and a 2.7-ml reduction in jowl volume compared to
pre-treatment measurements.1
"Part of the natural aging process is volume loss and a
downward shift, which makes our faces look more hollow and tired.
These long-term volumizing results are impressive because
strengthening the facial muscles with EMFACE can lift and move the
fat back up to the cheeks." adds Dr Halaas.
Facial volume improvement in a male patient 1 year after last
EMFACE treatment. Image courtesy of Dr Yael
Halaas, USA.
Additional insights were provided by a study from Dr
Manuskiatti, presented at the prestigious American Society for
Laser Medicine and Surgery (ASLMS) Conference in Baltimore, Maryland. In his study on Asian
patients, Dr. Manuskiatti observed an average 81% improvement in
skin firmness, and 93% of patients reported improvements via
self-evaluation six months after the initial treatments. The 3D
camera-assisted brow lift measurements showed the most significant
improvements at the same six-month time point.2
Dr. Manuskiatti's study represents the first longer-term
clinical research on EMFACE in Asian patients presented at a major
aesthetic medicine conference.
"The latest clinical evidence supports the expected long-term
outcomes of EMFACE. We are grateful for the collaboration with
exceptional researchers dedicated to bringing this important
data," concluded Tomas
Boleslavsky, Clinical Director at BTL.
About BTL
Founded in 1993, BTL has grown to become one of the world's
leading medical and aesthetic equipment manufacturers. With 500+
engineers and 3,000+ employees in over 80 countries, BTL offers
advanced non-invasive solutions for body-shaping, skin-tightening,
and other medical aesthetic treatments, including women's intimate
health and wellness. Among other brands, BTL's products include
EMSCULPT NEO®, EMFACE®, EXION™ ,
EMSELLA®, EXILIS® as well as their
proprietary HIFEM® and HIFES™ procedures. Please visit
www.btlaesthetics.com for additional information.
Sources:
1 Cohen, J., Halaas, Y., Chilukuri, S.,
Clark-Loeser, L., McCoy, J.D. (2024) Non-Invasive Restoration of
Facial Volume Loss: Synergistic Effects of HIFES & Synchronized
RF Technology in Facial Rejuvenation - A Retrospective Study.
Manuscript submitted for publication
2 Manuskiatti W., Evaluating the Efficacy and
Safety of Combined Synchronized Radiofrequency and HIFES
Stimulation for Facial Lifting in Asians: A 6-Month Analysis.
Presented at the American Society for Laser Medicine and Surgery
(ASLMS), Baltimore, Maryland,
April 11, 2024
Photo -
https://mma.prnewswire.com/media/2486650/BTL_EMFACE_Treatment.jpg
View original content to download
multimedia:https://www.prnewswire.co.uk/news-releases/experts-agree-on-the-longevity-of-emfaces-non-invasive-face-lifting-effects-302227401.html